naphthalimides has been researched along with Cancer of Prostate in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carling, D; Graham, R; Kent, TR; Muckett, P; Nikitin, AY; Penfold, L; Pollard, A; Woods, A; Zhang, S | 1 |
| Bontempi, G; Bruyère, C; Darro, F; De Nève, N; Decaestecker, C; Dehoux, MJ; Dewelle, J; Haibe-Kains, B; Kiss, R; Mahieu, T; Mijatovic, T; Simon, G; van der Aar, E; Van Quaquebeke, E | 1 |
| Dorr, RT; Landowski, TH; Pourpak, A | 1 |
| Ahmann, F; Blumenstein, B; Craig, JB; Crawford, ED; Eisenberger, M; Marshall, ME; Thompson, IM | 1 |
| Craig, JB; Hardy, J; Harman, G; Havlin, K; Koeller, J; Kuhn, JG; Melink, TJ; Phillips, J; Saez, R; Weiss, GR | 1 |
2 trial(s) available for naphthalimides and Cancer of Prostate
| Article | Year |
|---|---|
Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study.
Topics: Adenine; Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Humans; Imides; Isoquinolines; Male; Middle Aged; Naphthalimides; Neoplasms, Hormone-Dependent; Organophosphonates; Prostatic Neoplasms; Remission Induction | 1994 |
Phase I clinical investigation of amonafide.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Drug Evaluation; Female; Half-Life; Humans; Imides; Isoquinolines; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Naphthalimides; Organophosphonates; Prostatic Neoplasms | 1989 |
3 other study(ies) available for naphthalimides and Cancer of Prostate
| Article | Year |
|---|---|
CAMKK2 Promotes Prostate Cancer Independently of AMPK via Increased Lipogenesis.
Topics: Adenocarcinoma; AMP-Activated Protein Kinases; Animals; Benzimidazoles; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; CRISPR-Cas Systems; Female; Gene Deletion; Humans; Lipogenesis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Naphthalimides; Neoplasm Invasiveness; Phosphorylation; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction | 2018 |
UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Chemokines, CXC; Disease Models, Animal; Humans; Kinetics; Male; Mice; Naphthalimides; Neoplasm Transplantation; Prostatic Neoplasms; Urea | 2008 |
Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Catenated; DNA, Kinetoplast; Docetaxel; Humans; Isoquinolines; Male; Melphalan; Mice; Mice, SCID; Mitoxantrone; Naphthalimides; Prostatic Neoplasms; Protein Binding; Quinoxalines; RNA Interference; Taxoids; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2007 |